Targeting the PI3K/AKT pathway: a potential new weapon in the global fight against SARS-CoV-2?

ABSTRACT: Commentary on 'Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19' by Sun et al.

SUBMITTER: Santamaria S 

PROVIDER: S-EPMC8326129 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature